Purpose Itraconazole, a US Food and Drug Administration–approved antifungal drug,
inhibits the Hedgehog (HH) signaling pathway, a crucial driver of basal cell carcinoma (BCC) …

… squamous cell carcinoma. Patients with locally advanced cutaneous squamous cell carcinoma
… of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma. …

… We did an open-label, single-arm, multicentre phase 2 study. Eligible patients had advanced
squamous-cell carcinoma, adenosquamous-cell carcinoma, or adenocarcinoma of the …

… Further evaluation of STEVIE showed that 51 patients (4%) with advanced BCC experienced
cutaneous squamous cell carcinoma (SCC). Most patients were aged >75 years with …

Purpose To evaluate the efficacy and safety of the epidermal growth factor receptor–directed
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …

… open-label trial, adult patients with histologically confirmed locally advanced basal cell
carcinoma or metastatic basal cell carcinoma … Patients with locally advanced basal cell carcinoma …

… Because our study was open label, we did not mask patients or investigators to treatment
assignment. However, the funder was unaware of the aggregated by-treatment data summary …

… an open-label, multicentre, phase 1b trial of patients with recurrent or metastatic squamous
cell carcinoma … of recurrent or metastatic squamous cell carcinoma of the head and neck, and …

BACKGROUND: The treatment of recurrent transitional cell carcinoma (TCC) remains an unmet
clinical need. This study assessed lapatinib, a dual tyrosine kinase inhibitor of epidermal …

Background Merkel cell carcinoma is a rare, aggressive skin cancer with poor prognosis in
patients with advanced disease. Current standard care uses various cytotoxic chemotherapy …